Press Releases

Tyrosine Kinase Inhibitors Market is projected to surpass US$ 19.0 Bn by 2026

Share This Article

Tyrosine Kinase Inhibitors Market – Snapshot

The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe. The global tyrosine kinase inhibitors market was valued at more than US$ 18.0 Bn in 2017 and is projected to surpass US$ 19.0 Bn by 2026, expanding at a negative compound annual growth rate (CAGR) during the forecast period. The global market is witnessing expansion at a relatively higher growth rate owing to increasing expenditure on health care and high prevalence and increase in incidence of cancer across the globe.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111984

Cancer is the unregulated growth of body cells due to genetic mutations in its differentiation regulatory genes. Tyrosine kinases are enzymes that signal the cell differentiation cycle, mutation in their expression genes leads to their over expression, which results in uncontrolled proliferation of cells to form tumors. Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface. This binding blocks the phosphorylation by blocking adenosine tri-phosphate (ATP) biding to the receptor. Based on type of kinase receptors being targeted, tyrosine kinase inhibitors can be classified into BCR-ABL TKIs, EGFR TKIs, VEGFR TKIs, Janus Kinase Inhibitors, BTK inhibitors.

Tyrosine kinase inhibitors (TKIs) aid patients suffering from different cancer diseases. Tyrosine kinase inhibitors were accepted largely due to specificity and efficacy and the benefits these offer over chemotherapy and radiotherapy. High prevalence and incidence rates of cancer diseases such as chronic myeloid leukemia (CML), lung cancer, breast cancer, and renal cell cancer, and expanding indications of existing and pipeline on TKIs have expanded the indication areas of existing and pipeline on tyrosine kinase inhibitors in order to address various unmet needs and extend the product lifecycle. These factors, collectively, are projected to drive the global tyrosine kinase inhibitors market in the near future. Furthermore, rise in awareness about cancer diagnosis and treatment and surge in adoption in underdeveloped and developing markets are key factors that are estimated to fuel the tyrosine kinase inhibitors market in the near future

The global tyrosine kinase inhibitors market has been broadly segmented based on product, application, distribution channel, and region. In terms of product, the global market has been classified into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors, and other tyrosine kinase inhibitors. BCR-ABL tyrosine kinase inhibitors were one of the first approved TKIs for cancer treatment. Their wide acceptance and indications have contributed to their significant share in the global market. VEGFR tyrosine kinase inhibitors are projected to be a highly promising class of TKIs. Several companies have developed their VEGFR TKIs drugs with features of multi kinase receptor inhibition. These factors are likely to augment the segment by the end of 2026. In terms of application, lung cancer is the leading cause of cancer deaths in the world. TKIs such as EGFR, ALK, and HGFR have been in use for treating lung cancers. Increase in incidence of lung cancer is likely to propel the segment.

View full report@ https://qyresearchmedical.com/report/tyrosine-kinase-inhibitors-market-product-bcr-abl-tyrosine-kinase-inhibitor-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitors-vascular-endothelial-growth-factor-vegfr-tyrosine-kinase-inhibito-018-2030/111984

In terms of distribution channel, the global tyrosine kinase inhibitors market has been segregated into hospital pharmacies, independent pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a prominent share of the market. International and regional pharmacy service providers are expanding their operations across the regions, this is attributed to strong infrastructure network for distribution, thereby contributing to the dominant share held by the independent pharmacies segment of the global tyrosine kinase inhibitors market. Consolidation among independent pharmacies and their expanding operations across regions are likely to propel the independent pharmacies segment in the global market. Increase in adoption of e-commerce and convenience offered by online pharmacies are expected to drive the adoption of online pharmacies in developed markets.

In terms of region, the global tyrosine kinase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market; however, it is projected to gain market share by the end of 2026. The market in North America is primarily driven by the high cost of TKIs and high health care expenditure, which have contributed to the leading share held by North America. Furthermore, demand for advanced treatment options such as targeted therapies has contributed to the leading share held by the region. Recent patent expiry of several blockbuster TKIs has negatively impacted the market in North America. However, the introduction of new TKIs, such as JAK TKIs, multi-targeted TKIs, ALT TKIs, and others has compensated for the impact, which is projected to fuel the TKIs market in North America during the forecast period. The tyrosine kinase inhibitors market in Asia Pacific is projected to expand at a rapid pace during the forecast period. Rest of Asia Pacific countries dominated the tyrosine kinase inhibitors market in Asia Pacific, while the market in China and India is estimated to expand at a significant CAGR during the forecast period.

Companies such as Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson accounted for a major share of the global tyrosine kinase inhibitors market in 2017. In May 2018, Pfizer’s XALKORI (crizotinib) received FDA breakthrough therapy designation in two new indications. This is expected to increase the company’s therapy segment research in the near future. Other global players operating in the market include AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., , Eisai Co., Ltd., and Eurofarma Laboratórios S/A, who are focused on strategic acquisitions and collaborations with parallel companies in order to improve and strengthen their geographic presence in the international market.

Presently, commercially available tyrosine kinase inhibitors are indicated for treating non-small cell lung cancer, renal cell cancer, breast cancer, chronic myeloid leukemia, hepatocellular carcinoma, and breast cancer. These drugs are indicated as monotherapy or combination therapy, along with chemotherapy or as post-surgical resection remedy. However, tyrosine kinase inhibitors are not available for other cancer types such as neuroendocrine tumors.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111984/2900

According to the National Cancer Institute of the U.S., around 1,735,350 new cancer cases were diagnosed in the U.S. in 2018. Moreover, the U.S. had 15.5 million cancer survivors in 2016, which is projected to increase to 20.3 million by 2026.

Surge in Adoption in Underdeveloped and Developing Markets

Awareness about cancer diagnosis and treatment is being spread across the globe. Governing bodies are taking initiatives to provide access to healthcare to public at large.

Easing of norms for drug import, initiatives to attract health care providers & pharmaceutical companies to establish their base, and drug pricing regulations are likely to drive the oncology market. This, in turn, is projected to augment the tyrosine kinase inhibitors market.

Availability of generics in underdeveloped and developing markets is anticipated to spur adoption of tyrosine kinase inhibitors

Global tyrosine kinase inhibitors market has been segmented as given below:

By Product

  • BCR-ABL Tyrosine Kinase Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
  • Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
  • Other Tyrosine Kinase Inhibitors (Janus Kinase Inhibitors, Bruton’s Kinase Inhibitor, HGFR TKIs, ALK / ROS1 TKIs, etc.)

By Application

  • Chronic Myeloid Leukemia (CML)
  • Lung Cancer
  • Breast Cancer
  • Renal Cell Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Independent Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • Saudi Arabia
  • UAE
  • Rest of Middle East
  • Africa
  • South Africa
  • Rest of Africa

TABLE OF CONTENT

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Tyrosine Kinase Inhibitors Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.3.4. Key Trends
4.4. Global Tyrosine Kinase Inhibitors Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)

5. Global Tyrosine Kinase Inhibitors Market Outlook
5.1. Key Brand / Product Analysis
5.2. Patent & Market Exclusivity Analysis
5.3. Overview of Approved Indications
5.4. Tyrosine Kinase Inhibitors – Clinical Trial Analysis
5.5. Recent Industry Developments
5.6. Pipeline Analysis
5.7. Key Mergers & Acquisitions

6. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
6.3.1. BCR-ABL Tyrosine Kinase Inhibitors
6.3.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
6.3.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
6.3.4. Other Tyrosine Kinase Inhibitors
6.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Product

7. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
7.3.1. Chronic Myeloid Leukemia (CML)
7.3.2. Lung Cancer
7.3.3. Breast Cancer
7.3.4. Renal Cell Cancer
7.3.5. Others
7.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Application

8. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Global Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
8.3.1. Hospital Pharmacies
8.3.2. Independent Pharmacies
8.3.3. Online Pharmacies
8.4. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Distribution Channel

9. Global Tyrosine Kinase Inhibitors Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Tyrosine Kinase Inhibitors Market Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East &Africa
9.3. Global Tyrosine Kinase Inhibitors Market Attractiveness, by Country/Region

10. North America Tyrosine Kinase Inhibitors Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. North America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
10.2.1. BCR-ABL Tyrosine Kinase Inhibitors
10.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
10.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
10.2.4. Other Tyrosine Kinase Inhibitors
10.3. North America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
10.3.1. Chronic Myeloid Leukemia (CML)
10.3.2. Lung Cancer
10.3.3. Breast Cancer
10.3.4. Renal Cell Cancer
10.3.5. Others
10.4. North America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Independent Pharmacies
10.4.3. Online Pharmacies
10.5. North America Tyrosine Kinase Inhibitors Market Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6. North America Tyrosine Kinase Inhibitors Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country

11. Europe Tyrosine Kinase Inhibitors Market Analysis and Forecast
11.1.Introduction
11.1.1. Key Findings
11.2. Europe Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
11.2.1. BCR-ABL Tyrosine Kinase Inhibitors
11.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
11.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
11.2.4. Other Tyrosine Kinase Inhibitors
11.3. Europe Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
11.3.1. Chronic Myeloid Leukemia (CML)
11.3.2. Lung Cancer
11.3.3. Breast Cancer
11.3.4. Renal Cell Cancer
11.3.5. Others
11.4. Europe Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Independent Pharmacies
11.4.3. Online Pharmacies
11.5. Europe Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Europe Tyrosine Kinase Inhibitors Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country

12. Asia Pacific Tyrosine Kinase Inhibitors Market Analysis and Forecast
12.1.Introduction
12.1.1. Key Findings
12.2. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
12.2.1. BCR-ABL Tyrosine Kinase Inhibitors
12.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
12.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
12.2.4. Other Tyrosine Kinase Inhibitors
12.3. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
12.3.1. Chronic Myeloid Leukemia (CML)
12.3.2. Lung Cancer
12.3.3. Breast Cancer
12.3.4. Renal Cell Cancer
12.3.5. Others
12.4. Asia Pacific Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Independent Pharmacies
12.4.3. Online Pharmacies
12.5.Market Forecast, by Country, 2016–2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Asia Pacific Tyrosine Kinase Inhibitors Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country

13. Latin America Tyrosine Kinase Inhibitors Market Analysis and Forecast
13.1.Introduction
13.1.1. Key Findings
13.2. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
13.2.1. BCR-ABL Tyrosine Kinase Inhibitors
13.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
13.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
13.2.4. Other Tyrosine Kinase Inhibitors
13.3. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
13.3.1. Chronic Myeloid Leukemia (CML)
13.3.2. Lung Cancer
13.3.3. Breast Cancer
13.3.4. Renal Cell Cancer
13.3.5. Others
13.4. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Independent Pharmacies
13.4.3. Online Pharmacies
13.5. Latin America Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-region, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Latin America Tyrosine Kinase Inhibitors Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country

14. Middle East Tyrosine Kinase Inhibitors Market Analysis and Forecast
14.1.Introduction
14.1.1. Key Findings
14.2. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
14.2.1. BCR-ABL Tyrosine Kinase Inhibitors
14.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
14.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
14.2.4. Other Tyrosine Kinase Inhibitors
14.3. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
14.3.1. Chronic Myeloid Leukemia (CML)
14.3.2. Lung Cancer
14.3.3. Breast Cancer
14.3.4. Renal Cell Cancer
14.3.5. Others
14.4. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Independent Pharmacies
14.4.3. Online Pharmacies
14.5. Middle East Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016–2026
14.5.1. UAE
14.5.2. Saudi Arabia
14.5.3. Rest of Middle East & Africa
14.6. Middle East Tyrosine Kinase Inhibitors Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country

15. Africa Tyrosine Kinase Inhibitors Market Analysis and Forecast
15.1.Introduction
15.1.1. Key Findings
15.2. Africa Tyrosine Kinase Inhibitors Market Forecast, by Product, 2016–2026
15.2.1. BCR-ABL Tyrosine Kinase Inhibitors
15.2.2. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
15.2.3. Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
15.2.4. Other Tyrosine Kinase Inhibitors
15.3. Africa Tyrosine Kinase Inhibitors Market Forecast, by Application, 2016–2026
15.3.1. Chronic Myeloid Leukemia (CML)
15.3.2. Lung Cancer
15.3.3. Breast Cancer
15.3.4. Renal Cell Cancer
15.3.5. Others
15.4. Africa Tyrosine Kinase Inhibitors Market Forecast, by Distribution Channel, 2016–2026
15.4.1. Hospital Pharmacies
15.4.2. Independent Pharmacies
15.4.3. Online Pharmacies
15.5. Africa Tyrosine Kinase Inhibitors Market Forecast, by Country/Sub-regions, 2016–2026
15.5.1. South Africa
15.5.2. Rest of Africa
15.6. Africa Tyrosine Kinase Inhibitors Market Attractiveness Analysis
15.6.1. By Product
15.6.2. By Application
15.6.3. By Distribution Channel

16. Competition Landscape
16.1.Market Player – Competition Matrix (By Tier and Size of companies)
16.2.Global Tyrosine Kinase Inhibitors Market Snapshot of Companies (2017)
16.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
16.3.1. AstraZeneca Plc
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. Pfizer, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Novartis AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. Bristol-Myers Squibb Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Bayer AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. Boehringer Ingelheim International GmbH
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.6.5. Financial
16.3.7. F. Hoffmann-La Roche Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Johnson & Johnson
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Eisai Co., Ltd.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview
16.3.10. Eurofarma Laboratórios S/A
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111984/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button